- Financial Times•5 days ago
Vaccine research has a long history, dating back to Edward Jenner's first inoculation against smallpox in 1796. But today the field is growing vigorously, propelled by a rising world demand to fight existing ...
- Moody's•6 days ago
Takeda Pharmaceutical Company Limited -- Moody's: Japan economic momentum building, on the back of rising exports and expected fiscal support
Announcement: Moody's: Japan economic momentum building, on the back of rising exports and expected fiscal support. Global Credit Research- 18 Apr 2017. Tokyo, April 18, 2017-- Moody's Japan K.K. has released ...
- Reuters•19 days ago
Japan's Takeda Pharmaceutical said on Wednesday it had completed enrolment for a 20,000-subject dengue vaccine trial, the largest clinical study in its history, signalling the global ambitions of its vaccine business. Japan's largest drugmaker has taken a conscious decision to become more international under its French CEO Christophe Weber, who took over in 2015. The international dengue study will test the experimental vaccine on 20,100 children and adolescents in eight countries in Latin America and Asia where the mosquito-borne disease is endemic.
TKPYY : Summary for TAKEDA PHARMACEUTI SPON ADR EA - Yahoo Finance
Takeda Pharmaceutical Company Limited (TKPYY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||24.27 - 24.30|
|52 Week Range||19.96 - 25.05|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||31.98|
|Dividend & Yield||0.78 (3.31%)|
|1y Target Est||N/A|